References
- Bristol-Myers Squibb to Acquire IFM Therapeutics to Strengthen Oncology Pipeline Focus on Innate Immunity. https://news.bms.com/press-release/partnering-news/bristol-myers-squibb-acquire-ifm-therapeutics-strengthen-oncology-pipe.
- IFM Therapeutics website. www.ifmthera.com/.
- CSL Behring to Acquire Biotech Company Calimmune and its Proprietary Stem Cell Gene Therapy Platform. www.prnewswire.com/news-releases/csl-behring-to-acquire-biotech-company-calimmune-and-its-proprietary-stem-cell-gene-therapy-platform-300510086.html.
- Calimmune. www.calimmune.com/.
- CSL Behring. www.cslbehring.com/products.
- Gilead Sciences to Acquire Kite Pharma for $11.9 Billion. www.gilead.com/news/press-releases/2017/8/gilead-sciences-to-acquire-kite-pharma-for-119-billion.
- Kite Pharma website. www.kitepharma.com/.
- Celularity, Inc., Accelerates Breakthrough Placental Discovery & Therapeutic Platform. www.prnewswire.com/news-releases/celularity-inc-accelerates-breakthrough-placental-discovery–therapeutic-platform-300507278.html.
- Sorrento Therapeutics. http://sorrentotherapeutics.com/.
- United Therapeutics. www.unither.com/index.html.
- Human Longevity. www.humanlongevity.com/.
- Mundipharma and CellAct announce new deal for the worldwide development and commercialization of smart chemotherapy CAP7.1. www.mundipharma.com/docs/default-source/press-releases-library/cellact-release-100817.pdf?sfvrsn=0.
- Topas Therapeutics signs multi-year research and option agreement with Lilly focused on immune tolerance. http://topas-therapeutics.com/topas/news/press-releases/topas-therapeutics-signs-multi-year-research-and-option-agreement-with-lilly-focused-on-immune-tolerance.html.
- Topas Therapeutics. http://topas-therapeutics.com/topas/home/.
- Ethris Enters Strategic Collaboration With AstraZeneca and MedImmune to Develop mRNA Therapies for Respiratory Disease. http://ethris.com/wp-content/uploads/2017/08/170821_Ethris_MEDI_AZ_EN_FINAL.pdf.
- Ethris. http://ethris.com/.
- Caprion Biosciences. www.caprion.com/.
- Caprion Biosciences and the FNIH Biomarkers Consortium Partner to Improve Monitoring of Early Alzheimer's Disease Progression and Treatment Response. www.prnewswire.com/news-releases/caprion-biosciences-and-the-fnih-biomarkers-consortium-partner-to-improve-monitoring-of-early-alzheimers-disease-progression-and-treatment-response-641492463.html.
- Biomarkers Consortium - Longitudinal Proteomic Changes in CSF from ADNI: Towards Better Defining the Trajectory of Prodromal and Early Alzheimer's Disease. https://fnih.org/what-we-do/biomarkers-consortium/programs/longitudinal-csf-proteomics.
- Spellman DS Wildsmith KR Honigberg LA Tuefferd M Baker D Raghavan N et al. Development and evaluation of a multiplexed mass spectrometry based assay for measuring candidate peptide biomarkers in Alzheimer's Disease Neuroimaging Initiative (ADNI) CSF Volume. Proteomics Clin. Appl.9 (7–8), 715–731 (2015).
- Daiichi Sankyo Enters Worldwide Licensing Agreement with Boston Pharmaceuticals for a Highly Selective RET Inhibitor for Solid Tumors. www.prnewswire.com/news-releases/daiichi-sankyo-enters-worldwide-licensing-agreement-with-boston-pharmaceuticals-for-a-highly-selective-ret-inhibitor-for-solid-tumors-300510056.html.
- Boston Pharmaceuticals. www.bostonpharmaceuticals.com.
- Genmab and Seattle Genetics to Co-develop Tisotumab Vedotin for Solid Tumors. https://globenewswire.com/news-release/2017/08/29/1101629/0/en/Genmab-and-Seattle-Genetics-to-Co-develop-Tisotumab-Vedotin-for-Solid-Tumors.html.
- Genmab. www.genmab.com/.
- Seattle Genetics. www.seattlegenetics.com/.
- FDA approval brings first gene therapy to the United States. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm574058.htm.
- Entry for Actemra® on Drugs@FDA. www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125276.
- Medicines for Malaria Venture. www.mmv.org/.
- Novartis and Medicines for Malaria Venture launch patient trial in Africa for KAF156, a novel compound against multidrug-resistant malaria. www.novartis.com/news/media-releases/novartis-and-medicines-malaria-venture-launch-patient-trial-africa-kaf156-novel.
- Daiichi Sankyo Announces Positive Top-line Results from Phase 3 Clinical Trial Evaluating Mirogabalin in Diabetic Peripheral Neuropathic Pain. www.prnewswire.com/news-releases/daiichi-sankyo-announces-positive-top-line-results-from-phase-3-clinical-trial-evaluating-mirogabalin-in-diabetic-peripheral-neuropathic-pain-300511945.html.
- European Patent Office to Grant MilliporeSigma's Patent Application for CRISPR Technology. www.prnewswire.com/news-releases/european-patent-office-to-grant-milliporesigmas-patent-application-for-crispr-technology-300497741.html.
- Sigma Aldrich Co. LLC, EP 3138910 (2017).
- Philippidus A . MilliporeSigma to Be Granted European Patent for CRISPR Technology. www.genengnews.com/gen-news-highlights/milliporesigma-to-be-granted-european-patent-for-crispr-technology/81254776.
- Cohen J . CRISPR patent battle in Europe takes a ‘wild’ twist with surprising player. www.sciencemag.org/news/2017/08/crispr-patent-battle-europe-takes-wild-twist-surprising-player.